Biomarin Pharmaceutical Inc (BMRN)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 541,763 | 188,563 | 149,576 | -75,350 | -48,997 |
| Revenue | US$ in thousands | 2,845,320 | 2,374,190 | 2,068,670 | 1,832,750 | 1,823,140 |
| Pretax margin | 19.04% | 7.94% | 7.23% | -4.11% | -2.69% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $541,763K ÷ $2,845,320K
= 19.04%
Based on the provided data, Biomarin Pharmaceutical Inc's pretax margin has shown fluctuations over the past five years. The company reported negative pretax margins in the fiscal years ending December 31, 2020, and December 31, 2021, indicating that the company's expenses exceeded its revenues before accounting for taxes during these periods.
However, there was a notable turnaround in the fiscal year ending December 31, 2022, with a positive pretax margin of 7.23%. This improvement was further sustained in the following years, with pretax margins of 7.94% in 2023 and a significant increase to 19.04% in 2024.
The consecutive increase in pretax margins from 2022 to 2024 suggests that Biomarin Pharmaceutical Inc has been able to effectively manage its expenses and increase revenue generation, leading to healthier profitability before taxes. This positive trend indicates potential operational efficiencies and strategic initiatives that have positively impacted the company's financial performance.
Peer comparison
Dec 31, 2024